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Abstract 
Predicting the response of a specific cancer to a therapy is a major goal in modern oncology that should 
ultimately lead to a personalised treatment. High-throughput screenings of potentially active compounds 
against a panel of genomically heterogeneous cancer cell lines have unveiled multiple relationships 
between genomic alterations and drug responses. Various computational approaches have been 
proposed to predict sensitivity based on genomic features, while others have used the chemical 
properties of the drugs to ascertain their effect. In an effort to integrate these complementary approaches, 
we developed machine learning models to predict the response of cancer cell lines to drug treatment, 
quantified through IC50 values, based on both the genomic features of the cell lines and the chemical 
properties of the considered drugs. Models predicted IC50 values in a 8-fold cross-validation and an 
independent blind test with coefficient of determination R2 of 0.72 and 0.64 respectively. Furthermore, 
models were able to predict with comparable accuracy (R2 of 0.61) IC50s of cell lines from a tissue not 
used in the training stage. Our in silico models can be used to optimise the experimental design of drug-
cell screenings by estimating a large proportion of missing IC50 values rather than experimentally 
measure them. The implications of our results go beyond virtual drug screening design: potentially 
thousands of drugs could be probed in silico to systematically test their potential efficacy as anti-tumour 
agents based on their structure, thus providing a computational framework to identify new drug 
repositioning opportunities as well as ultimately be useful for personalized medicine by linking the 
genomic traits of patients to drug sensitivity.  
 
Introduction 
High-throughput screening of a large number of molecules is a widely used approach to identify lead 
compounds exerting a beneficial effect on a given phenotype. In the context of cancer, libraries of 
chemical entities have been tested in this way against panels of cell lines grown in different conditions 
and with heterogeneous genomic backgrounds [1]. Following the pioneering work of the “NCI-60”, a 
collection of 59 human cancer cell lines developed by the National Cancer Institute for in vitro drug 
screening [2], recent hallmark studies have shown that screening very large cell line collections can 
recapitulate known and identify novel molecular genomic determinants of drug sensitivity [1,3-5].  
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In these studies, using systematic statistical inference and regression methods, determinant such as 
oncogenic lesions, high or low levels of basal gene expression and other genotypic traits have been 
associated to profiles of increased sensitivity/resistance to specific compounds. For instance, by applying 
a multivariate analysis of variance [6] and the ‘Elastic Net’ regression framework [7] established drug-
genotype associations have been confirmed and complemented with markers of tissue-specificity and 
novel connections, e.g. the EWS-FLI1 translocation in Ewing’s sarcoma and sensitivity to PARP 
inhibitors, have been identified and further experimentally validated. Results of these studies have been 
made publicly available, providing unique resources that support the discovery of new predictive 
biomarkers for personalised cancer therapy. 
 
Increasing further the size of the considered cell-line/compound panels would be very beneficial, as it 
provides the basis to improve the accuracy and predictive power of the inferred associations. However, 
this requires larger infrastructures and the cost grows with the screening size. In addition, due to various 
technical and logistical reasons in a high-throughput screen [7], the resulting compound-by-cell line matrix 
of drug efficacy (typically summarised in their IC50, the half maximal (50%) inhibitory concentration of a 
substance with respect to cell viability) is often not complete. Although many steps are automated, filling 
experimentally each gap could be expensive and laborious [6]. Hence, an accurate tool to impute missing 
IC50s and estimate them for novel cell lines would be of great value for drug screening design. 
Furthermore, a robust prediction tool for in silico identification of potentially effective drugs for treating a 
specific cancer could be used for drug repositioning [8,9]. An approach of this kind is represented by the 
COMPARE algorithm [10,11] that uses drug response profiles of the NCI-60 screening, through a ‘guilt-
by-association’ paradigm. Following this principle, drugs eliciting a similar drug-response profile across 
the cell lines in the NCI-60 panel are hypothesized to share a common mode of action (MoA), thus 
enabling MoA discovery for novel drugs (if their tumour-suppression profile is similar to that of a known 
and well characterized drug) as well as the discovery of novel or secondary effects for established drugs. 
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Ultimately, in silico methods to accurately predict the effectiveness of drugs based on the molecular 
making of tumours (i.e. genome, transcriptome) would be a major milestone towards personalized 
therapies for cancer patients based on molecular biomarkers [12]. 
 
Results 
We therefore investigated whether it is possible to build machine learning models (for details see 
“Materials and Methods” section, “Machine learning” subsection) that can predict drug sensitivity using 
cell line screening experimental data, where cell lines are treated with variable concentration of a given 
drug and the resulting dose-response curve summarized by an IC50. We focused on the most 
comprehensive cancer drug screening dataset available to date, from the “Genomics of Drug Sensitivity 
in Cancer” (GDSC) project [3]. For each drug, a neural network model was trained to predict its IC50 
profile across the panel of cell lines based on the genomic background of each cell, as characterised by 
microsatellite instability status (1 = unstable or 0 = stable), somatic coding variants in the coding 
sequence of 77 cancer genes (1 = any change in protein sequence and 0 = wild type) and copy number 
alterations denoting gene amplification and deletion of those cancer genes (1 = amplification / more than 
7 copy numbers, 0 = wild type / between 1 or 7 copy numbers, and -1 = deletion / no copy number). 
However, the predictive power of these initial models was limited, especially for those drugs without a 
well-known oncogene-to-drug response dependency.  
 
We reasoned that cancer cell sensitivity to drug molecules is driven by features from both cells and drugs. 
Whereas cell features are ultimately connected to the inner workings of the cell, drug features include 
physicochemical properties that are correlated with the ability of the molecule to cross the cell membrane 
(e.g. lipophilicity) or its selectivity to intracellular targets (e.g. fingerprints encoding the chemical 
structure).  
Indeed, extensive work has been done on Quantitative Structure-Activity Relationship (QSAR) 
approaches to predicting whole-cell activity of molecules based of their chemical properties [13-16], 
including applications to predicting anti-cancer activity in drugs [17,18]. However, such QSAR approaches 
exclusively based on chemical features cannot distinguish between resistant and sensitive cell lines. For 
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instance, building a model without any information of the cell lines, the model will be not capable of 
predicting cell line A to be more resistant than cell line B to drug C, which is the main aim of integrating 
chemical and genomic features in our models.  
 
We therefore extended our machine learning models to include as input chemical features from the drugs, 
besides the molecular characterization of the cell lines (see Fig 1). This integrative approach not only 
integrates two complementary streams of information, but also allows the model to be trained with much 
larger amounts of data, which is often a key factor to improve predictive performance (see Fig 2). 
Consequently, data was pre-processed to include 689 chemical descriptors of the drugs and 138 genomic 
features for differentiating the cell lines, resulting in an input space of 827 features.  
Chemical descriptors were generated with PaDEL software [19] from simplified molecular-input line entry 
system (SMILES) structures. Descriptors include physicochemical features such as weight, lipophilicity, 
rule of five, and additionally fingerprints of the drugs (for details see “Materials and Methods” section, 
“Features” subsection, and http://padel.nus.edu.sg/software/padeldescriptor/).  
For building our model, we used GDSC screening data from 608 genomically characterised cell lines and 
111 drugs for which chemical information were available (see Fig 2 and Methods for details). The 
published version of this matrix holds 38,930 IC50 values (~58% of the total, due to technical and logistic 
reasons).  
We performed an 8-fold cross-validation, where the test set of each fold was not used for training so as to 
measure the predictive power of the resulting models across all drugs rather than for each drug 
separately. Neural networks were able to impute missing log(IC50) values on the test sets with an 
averaged Pearson correlation coefficient (Rp), coefficient of determination (R2) and root mean square 
error (RMSE) (Text S1) of 0.85, 0.72 and 0.83 across all 111 drugs, respectively (Fig 3A). Alternatively, 
random forests achieved comparable performances (Rp of 0.85, R2 of 0.72 and RMSE of 0.84; full details 
in supplementary materials). Furthermore, we conducted a blind test using 13,565 new experimental IC50 
values only received after training our models in order to verify our cross-validation results (drug-to-cell 
line matrix updated by ~18%, with these newly generated IC50s exclusively used as the blind test set). 
The results on the blind test were almost as good as in the cross-validation, obtaining an Rp of 0.79, R2 of 
 6 
0.64 and an RMSE of 0.97 (Fig S1, Text S2). The accuracy of the predictions encouraged us to train the 
networks with fewer IC50 values. Remarkably, the predictive power of the models did not fall appreciably 
off in quality, even if the amount of training data was reduced to 20 % of the total (Fig 3B).  
 
Using an analysis of variance (ANOVA) to identify drug-to-oncogene associations, we investigated how 
well the IC50 values predicted for the test set using our model recapitulate associations manifested in the 
experimental data, for instance, whether a given mutation is causing sensitivity or resistance against a 
drug [3]. Using only predicted IC50 values, we correctly captured 79% (168/213) of the significant 
observations with the same t-test tendency (positive or negative effect on drug sensitivity) identified with 
the experimental IC50s. When only considering significant associations from our model (p-value adjusted 
with Benjamini-Hochberg, FDR=0.2), we correctly predicted 28% (59/213) of all experimentally identified 
associations. Where we failed to detect an association the ANOVA effect size is often small, or the 
experimental correlation is associated with a mutation either not or infrequently represented within the 
subset of cell lines with predicted IC50 values. Notably, as example of the utility of this approach, using 
only predicted IC50 values we identified known drug-to-oncogene associations such as sensitivity of 
BRAF-mutated cells lines to MEK1/2-inhibitors (Fig 4B) [20]. The range of predicted IC50 values for a drug 
are typically narrower than for the observed values and is likely because currently available genomic 
dataset are in sufficient to explain the observed range of drug responses across the cell lines. 
 
In addition, we assessed the predictive power of our model for unknown cell lines. Therefore, we applied 
a more stringent 8-fold cross-validation, where a cell line was either included in the train or test set. These 
models achieved an Rp of 0.82, R2 of 0.68 and an RMSE of 0.89 (Fig S2) demonstrating the accuracy of 
our model to predict IC50 values for completely new cell lines. In an additional simulation, we left out all 
cancer cell lines from a specific tissue, e.g. we removed all lung cancer cell lines (106 out of 608 cell 
lines) and still obtained an Rp of 0.79, R2 of 0.61 and RMSE of 0.99 (Fig S3). 
 
Discussion 
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Our results show that by using genomic features from the cell lines and chemical information from drugs, 
it is possible to build in silico multi-drug models to impute missing IC50 values with non-parametric 
machine learning algorithms such as neural networks and random forests. As output for our method, we 
chose to explore IC50 values as generated by Garnett et al. [3], which enables us to compare our results 
to them, however other metrics (such as a capped IC50 or area under the curve), might provide additional 
insight and potentially lead to more robust models. 
The Pearson correlation (Fig. 2A) and coefficient of determination (Fig. 2B) of the multi-drug model are 
significantly better than the single-drug models, while the RMSE error is similar (Fig 2C). This means that 
the error (on average) of predicting a given IC50 value is the same in the multi-drug and single-drug 
models (RMSE) and, since some drugs are active at different concentration ranges, the model is able to 
cover a much larger dynamic range with a similar precision. The coefficient of determination balances 
these two terms, and thus a broader range with the same RMSE increases R2. Thanks to the use of 
chemical descriptors, multi-drug models are trained with a volume of data that is two orders of magnitude 
bigger than the data to train each single-drug model. This larger dataset weights the difficulty in training 
heterogeneous response values across drugs. 
 
In several instances, the use of multi-drug models permitted the in silico identification of genomic events 
associated with altered drug sensitivity, which is only possible when genomic properties are considered.  
Although our models did not capture all known gene to drug associations, we anticipate that as larger 
drug sensitivity and genomic datasets become available in coming years the predictive power of these 
models will increase. We believe that the predictive power of our models is due to the large number of cell 
lines and broad range of drugs in the GDSC panel that samples intensively the chemical space of 
common cancer drugs (chemotherapeutic and kinase inhibitors). It remains to be determined how these 
models will predict completely unknown families of therapeutic agents.  
 
The predictive ability of our methods for individual values is still limited and could be further improved by 
extending the set of input features with additional layers of molecular characterization of the cell lines, 
such as basal transcriptional profiles and phosphoproteomic data. These data types have been used to 
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predict drug responses in various contexts [21-24]. Another valuable extension could be the inclusion of 
gene expression data following drug treatment, a powerful in silico resource for predicting treatment 
outcomes and elucidating compound mode of action [25,26], as well as a promising gateway to the 
identification of new drug repositioning opportunities [27]. Additionally, epigenetics data could enhance 
the prediction capabilities of future methods [28].  
Our method uses purely experimental data, but additional predictive power can be expected from 
including knowledge of the underlying network [29]. It has been shown that the prediction of drug 
response and mode of action by transcriptional profiling is significantly enhanced when paired with known 
a priori gene and protein networks [30,31] and drug similarities have been inferred based on the 
corresponding in silico predicted impinged pathway [32]. Prior knowledge could also increase the 
interpretability of the results. Known regulatory relationships between genes and transcriptional data [33] 
and protein networks [34] can be used to identify deregulated pathways, and be further linked to the 
genomic alterations that drive them [35], highlighting subnetworks of importance for drug response. 
Incorporation of these additional features will require a scheme to prioritize the input features based on 
their impact on the final trained model. Associations between features and outcomes could be explicitly 
unveiled by integrating in our models feature selections criteria and dimensionality reduction techniques.  
In terms of predictive models, we have used standard machine learning methods (neural networks and 
random forests), given their flexibility and robustness as predictive models. A fertile ground for further 
research is investigating the application of other modeling techniques, including linear regression 
methods (e.g. LASSO, ElasticNets).  
 
Our results also show that one can estimate the accuracy of prediction for different degrees of 
sparseness in the data, which may have utility when designing experiments where coverage has to be 
balanced with accuracy. Furthermore, because models are able to predict IC50 on cell lines not screened 
yet, predictions from these models can be used to decide whether it is worthwhile expanding the panel of 
cell lines, or rather focus on a few selected ones.  
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The implications of our results go beyond their utility to optimise the experimental design of drug 
screenings. Once a model is built, it could be used to systematically test the potential effect of novel 
drugs in silico, based on their chemical features and similarity. These predictions can help to evaluate the 
potential activity of new drugs, e.g. from large chemical libraries, to be screened. Furthermore, predictions 
on clinically approved drugs is expected to reveal candidates for drug repurposing and potentially identify 
specific disease sub-types that would be most responsive [8]. Although cell lines are not an exact replica 
of real tumours, comprehensive predictive models such as ours together with expanded genomic and 
epigenomic datasets may be a good proxy to facilitate the development new therapeutic strategies 
tailored to individual patients [12].  
 
Materials and Methods 
Training dataset - We used the data from the Genomics of Drug Sensitivity in Cancer project [3], which 
contains 639 cancer cell lines, each of them characterised by a set of genomic features (details in the 
next section). The characterisation is not complete for every cell line, and therefore we filtered out cell 
lines with more than 15 missing genomic features, which reduced the set of selected cell lines from 639 to 
608. The dataset contains 131 drugs. As our method exploits the chemical structure of each drug, this 
information in simplified molecular-input line entry system (SMILES) format is required. Therefore, we did 
not consider the 20 drugs for which SMILES were not available, and built our model for the remaining 111 
drugs. 
The resulting matrix of 608 cell lines by 111 drugs will have 67,488 possible drug response curves, each 
summarised by its IC50 value (drug concentration in µM units required to eradicate 50% of the cancer 
cells). Currently, the dataset contains 38,930 IC50 values out of these 67,488 (58%), with missing values 
mostly due to logistic reasons such as co-ordinating measurements from various screening centres. The 
log IC50 ranges from -7.40 (IC50~4·10-8 M; the most sensitive drug-cell combination) to 6.91 (IC50~8·106 M; 
the most resistant). Note that extremely large and small values are extrapolations in the IC50 that have no 
clinical relevance. We use these ranges in this study as those are the ones used in the paper Garnett et 
al. [3] that we compare our results against. 
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Blind test dataset - We generated test sets during the cross-validation for estimating the expected error 
(details in cross-validation section). However, even cross-validation can overestimate the prospective 
performance of machine learning methods. Therefore, we conducted a truly blind test in order to 
demonstrate the prospective capabilities of our cross-validated models to impute missing IC50 values in 
the 608 cell lines by 111 drugs matrix (Fig S1). Our blind test contains 13,565 newly generated IC50 
values, which were obtained after training took place, or put it differently, a batch of new experimental 
data was generated to independently validate our models. To sum up, 58% of the IC50 values are in the 
original dataset (used for cross-validation), an additional 18% are used for the blind test (independent 
test). 
 
Features - There are two different input data streams in our method: the genomic background for each 
cancer cell line, and the chemical properties of a drug. For the first input data stream, cancer cell lines are 
characterised by the mutational status of 77 oncogenes, where each of them is further described by copy 
number variation (any high grade amplification or homozygous deletion of a cancer gene) and sequence 
variation (changes in the protein sequence, e.g. non-synonymous single nucleotide polymorphism). 
Additionally, there is one binary feature for the microsatellite stability status of each cell line. The cell line 
features were encoded as followed: 
Microsatellite instability status  =
1 , if unstable
0 , if stable
!
"
#
$#
  
Sequence variation   =
1 , if mutation
0 , if wildtype
!
"
#
$#
 
Copy number variation   =
1
0
−1
, if amplification
, if wildtype
, if deletion
"
#
$$
%
$
$
  
All mutations considered, we have 77 possible copy number variations plus 77 possible sequence 
variations and one microsatellite stability value, which sums up to 155 possible cell line features. 
However, a few mutational features are missing for some cell lines, and we conservatively removed a 
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feature in case it was missing for any cell line. This led to a final set of 138 genomic features 
characterising each cancer cell line.  
The second input data stream incorporates 1D and 2D chemical properties of each drug. We generated 
these chemical features using the PaDEL software (v2.11, downloaded from the project website, 
http://padel.nus.edu.sg/software/padeldescriptor/) [19] from the SMILES with default settings. 722 
features are physicochemical descriptors and 881 are obtained from the fingerprints, leading to a total of 
1603 chemical features. We only included chemical features that could be calculated for all drugs. 
Furthermore, we removed any feature with the same value across all drugs, obtaining a final set of 689 
chemical features for each drug (e.g. atom count, bond count, molecular weight, xlogP or PubChem 
fingerprint, to name a few). The list of drugs is available in the Supplementary material (druglist.csv). 
Taking together the cancer cell line and drug stream, we used 827 features to build our predictive models 
of the log IC50 value of a given cell line in the presence of a given drug.  
 
Cross-validation - We used an 8-fold cross-validation for building our models. Therefore, we separated 
the original dataset into eight equally sized sets of IC50 values, obtained by randomly distributing all IC50s 
of the matrix into 8 bins. One of them was exclusively used for testing (never involved in any training), 
other six were destined for training the model and the remaining piece was used for cross-training. Cross-
validation is a process used to avoid under- and overfitting [36] e.g. identifying the optimal number of 
hidden units and training iterations for a neural network (details in “Machine learning” section). We rotated 
iteratively the sets so that each data point was used at least once for training, cross-training or testing. 
Finally, we obtained 8 models, which were equally predictive. 
Furthermore, we used a more stringent version of the above described 8-fold cross-validation. We 
ensured that test, train and cross-train set are not sharing any cell line, which might occur in the non-
stringent version (described above). For instance, assume cell line C1 is treated with the drugs D1, D2 
and D3; For the non-stringent cross-validation, the combination C1-D1, C1-D2 and C1-D3 might be 
distributed over test, train and cross-train set; for the stringent cross-validation, every combination with C1 
is exclusively occurring in one of those three sets. 
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Machine learning – For the neural networks, we used the Java implementation from Encog 3.0.1 
(http://www.heatonresearch.com/encog) [37,38] of a feed-forward multi layer perceptron, where we 
defined three different layers: input, hidden (or middle) and output layer. Every perceptron of a layer is 
completely connected to each perceptron of the upper layer. The number of features determined the 
number of input units, or put it differently, required perceptrons in the first layer. The number of hidden 
units was explored during the training for determining the correct model complexity, which was between 1 
and 30 hidden units. Furthermore, each input and hidden unit had also an bias, which is a permanent 
activation input for those perceptrons. We used a single output unit for predicting the continuous log(IC50) 
value.  
As perceptron activation function for enabling the network to predict non-linear behaviour, we used the 
sigmoid function, which returns values in an interval from 0 to 1. Therefore, we had to normalise the IC50 
values (raw IC50 values, not in log space) also into a range from 0 to 1, which was done with the following 
logistic-like function: 
norm y( ) = 11+ y−0.1 where y > 0  
y : Observed/expected IC50 value, which has to be a positive number greater than zero.
 
 
 
We trained the network with the resilient error backpropagation implementation from Encog with default 
parameters [39]. For exploring the final model complexity, which is described by number of hidden units 
and amount of training iterations, we examined different neural network architectures from 1 up to 30 
hidden units and trained them for maximal 400 iterations. We searched the global minimum in that cross-
training landscape (minimizing the root mean square error of cross training set) for avoiding an under- or 
overfitting (usually, between 21 and 27 hidden units were chosen as best model after approximately 300 
iterations).  
We also carried out random forest [40] regression models to investigate whether there was any significant 
performance gain using an alternative non-parametric machine learning methodology (Text S3). A 
random forest is an ensemble of many different regression trees randomly generated from the same 
training data (recommended value of n=500 trees was used).  
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Data access - The dataset is fully accessible of the Genomics of Drug Sensitivity in Cancer project [3], 
downloaded from the project website, http://www.cancerrxgene.org/. The training set is based on release 
v1.0 from June 2012. Newly generated IC50 values of the blind test are published in release v1.1 from 
July 2012, which are not part of Release v1.0.  
 
Software access – The Encog Machine Learning Framework (version 3.0.1) [37,38] containing the neural 
network implementation is a free available and open source (Apache License 2.5), and could be 
downloaded on the Heaton Research webpage (http://www.heatonresearch.com/encog). For the random 
forest model, the R package randomForest (version 4.6-6) [41] is also freely available under GPL licence 
from CRAN webpage (http://cran.r-project.org/web/packages/randomForest/index.html). 
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Figures: 
 
Figure 1: IC50 prediction workflow. Our method is based on two different input streams: (1) cell line 
features of 77 oncogenes and their mutation state, (2) drug features that are generated with PaDEL 
software [19] from the simplified molecular-input line entry system (SMILES), see method section for 
details. The continuous IC50 value is predicted with state-of-the-art machine learning algorithms (neural 
networks and random forests). 
 
 
Figure 2: Comparison of single-drug models and the multi-drug model. The performance of the 
multi-drug model (red asterisk) and the family of 111 single-drug models (blue histogram) is represented 
using three different metrics: (A) Pearson correlation Rp, (B) coefficient of determination R2, and (C) root 
mean square error RMSE. 
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Figure 3: IC50 prediction. Predictions are achieved with 8-fold cross-validations.  Performance values 
are exclusively calculated on the test sets. (A) Correlation between predicted to experimental observed 
log(IC50) values (Pearson correlation Rp =  0.85 ; coefficient of determination R2 = 0.72, root mean square 
error RMSE = 0.83). Although there is an enrichment of resistant cell lines, which tend to have higher 
log(IC50) values than sensitive cell lines, the lower log(IC50) values are still decently predicted. (B) 
Expected improvement of the IC50 prediction by filling experimentally gaps in the cell-to-drug matrix. The 
vertical grey line corresponds to the published data set (filled to ~58%, due to logistic reasons), which 
corresponds to the results in panel (A). However, similar accuracies (Rp of 0.84 instead of 0.85, R2 of 0.70 
instead of 0.72) can be achieved using exclusively 20 % of the whole matrix.  
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Figure 4: Comparing ANOVA with prediction. (A) Analysis of variance (ANOVA) of experimental data 
and predicted output for drug-to-oncogene associations (20% FDR). The size of each association (dot) is 
proportional to the amount of treated cell lines containing the particular mutated oncogene. Blue dots 
indicating the same t-test tendency in our predictions, and red ones the opposite. (B) Predicted and 
measured IC50s of BRAF-mutated vs. wild-type cell lines exposed to the MEK1/2-inhibitor PD-0325901 (p-	 
value of prediction = 1.91×10-05, t-test multiple hypothesis corrected with Benjamini & Hochberg).  
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Supplemental Materials 
 
Text S1: Measuring performance.  
The output of our method is the logarithm to base 10 of the IC50 in µM: 
y =log IC50( )  
y :  Prediction of log(IC50) by our method 
IC50 : Required concentration [µM] to eliminate 50% of the cancer cell population, computed as 
described in Garnett et al Nature 2012 
 
We evaluated three different performance metrics, (i) one that captures the linear dependency of the 
prediction versus observation, (ii) a metric for outlining the variance of an assumed perfect prediction and 
(iii) additionally another metric that describes the average error of the model predictions: 
 
(i) Pearson correlation coefficient (Rp) describes the relationship of prediction and observation. Rp is in a 
range from -1 to 1; negative correlations hint at inverse predictions (more predicted wrong than correct), 
Rp of 0 correspond to a random relationship (no correlation), and positive correlations indicate linear 
behaviour with positive gradient: 
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n :  Size of the test set 
y

pred : Vector of observed/expected log(IC50) value 
y

obs : Vector of predicted log(IC50) value 
 
(ii) Coefficient of determination (R2) measures the proportion of the variance of the data that is explained 
by the regression model. As regression model, we assume a linear function representing a perfect 
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prediction, or put a differently, plotting a line through observation-by-observation points. The following 
definition of R2 typically returns values in range from 0 to 1, where values closer to one indicate a good 
prediction and 0 suggest weak fitting of the observations. However, since the regression model is not 
data driven and rather a conservative assumption of being a perfect prediction, also negative values are 
possible in case the prediction is far off the observation.  
R2 =1−
(yobsi − ypredi )2i=1
n
∑
(yobsi − yobs )2i=1
n
∑
 
n :  Size of the test set 
yobs : Observed/expected log(IC50) value 
yobs : Average of all observed log(IC50) values 
ypred : Predicted log(IC50) value 
 
 
(ii) Root mean square error (RMSE) provides an average of the error across all predictions made by the 
models:  
RMSE = 1n (yobsi − ypredi )
2
i=1
n
∑  
n :  Size of the test set 
yobs : Observed/expected log(IC50) value 
ypred : Predicted log(IC50) value 
 
Text S2: Comparing performance of imputation methods and machine learning approach. A 
straightforward way to estimate missing IC50 values is to impute them from the rest of the values. We 
therefore compared our feature-based approach against conventional imputation methods on our blind 
test. We used well-known reference methods from the R package “imputation” v1.3 developed by Jeffrey 
Wong: Singular Value Threshold (SVT), Singular Value Decomposition (SVD), and k-Nearest Neighbor  
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(kNN) imputation. To estimate the parameters of each imputation method, we used cross validation as 
suggested in the example code of the R package. SVT imputation obtained 0.06 Rp and 1.66 RMSE. The 
SVD imputation improved the performance to 0.37 Rp and 1.54 RMSE. The best performing imputation 
method is kNN with 0.71 and 1.10 Rp and RMSE, respectively. Our method (in this case a neural network) 
including genomic and chemical drug properties outperformed all imputation methods with an Rp of 0.79, 
R2 of 0.72 and RMSE of 0.97. It is important to note that imputation techniques, unlike feature-based 
machine learning, cannot be used to extrapolate, i.e. to predict IC50s for unseen cell lines or drugs. 
	  
Text S3: Random Forest. In model building, we used the same training set, features and performance 
measures as in the neural network model. However, unlike in the neural network and for the sake of 
efficiency, we did not tune any parameter of the Random Forest and hence the 8-fold cross-validation 
was slightly different (i.e. the same test set used by the neural network model, but exploiting more training 
data with a control parameter-free Random Forest). Here all seven partitions are exclusively used for 
training and the last partition for test. As usual, the prediction on the eight independent folds, one per 
each regression, is averaged. 
In the case of randomly constructed partitions, RMSE was 0.84, R2 was 0.72 and the Rp was 0.85. In the 
case of leaving cells out partitions, RMSE was 0.85, R2 was 0.71 and the Rp was 0.84. The performance 
on the blind test was RMSE was 1.00, R2 was 0.59 and the Rp was 0.78. Overall, these results are very 
similar to those obtained with the neural network model. Each machine learning model was independently 
trained and validated using different computer codes, which further supports the robustness of our 
results. 
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Figure S1: Blind test of multi-drug model. The training dataset holds 38,930 IC50 values, that is ~58% 
of all possible drug-to-cell line combinations. For the blind test, 13,565 novel IC50 values were generated, 
an~18% additional data points which were not included in the training dataset. For obtaining the predicted 
log(IC50) values, we averaged the output of each model (8 different models resulting from the 8-fold 
cross-validation procedure). The prediction on the blind test was slightly worse than that estimated by 
cross-validation (Fig 3A): root mean square error (RMSE) was increased from 0.83 to 0.97, coefficient of 
determination (R2) declined from 0.72 to 0.64 and the Pearson correlation coefficient (Rp) was decreased 
from 0.85 to 0.79. This small performance decrease is due to the fact that blind test data points are not 
selected at random: these tend to come from drug-cell combinations that are not optimally represented in 
the training set (i.e. those cell lines in the training set that have been probed against every drug in the 
panel will not have further IC50 values in the test set, as all training and test sets in this study are non-
overlapping). 
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Figure S2: Correlation between predicted to experimental observed log(IC50) values leaving out 
cell lines. The stringent 8-fold cross-validation was performed on the distinct set of cell lines, so that a 
cell line was neither used for testing or involved in the training. The figure shows values obtained solely 
on the test sets. The prediction quality is slightly worse than the normal cross-validation (Figure 3A): 
RMSE increased from 0.83 to 0.89, R2 decreased from 0.72 to 0.68 and the Rp decreased from 0.85 to 
0.82.  
 
 
Figure S3: Correlation between predicted to experimental observed log(IC50) values leaving out all 
lung cell lines. To further challenge our model and our hypothesis that it is possible to leave out several 
cell lines, we removed all lung cell lines and used them exclusively for testing. There are 106 out of 608 
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cell lines are from lung tissue (~17 % from data), which we were able to predict with minor performance 
reduction compared to including all cell lines (Figure 3A): root mean square error (RMSE) increased from 
0.83 to 0.99, coefficient of determination (R2) declined from 0.72 to 0.61 and the Pearson correlation 
coefficient (Rp) decreased from 0.85 to 0.79. 
 
